Abstract | OBJECTIVE: STUDY DESIGN: Randomized, double-blind, crossover study. SETTING: Tertiary neurotologic and audiologic center with additional referrals from a secondary university hospital center. PATIENTS: Twenty-four adult patients with tinnitus were randomized into the study. MAIN OUTCOME MEASURES: Visual analogue scale (VAS) measurements of tinnitus loudness (intensity), pitch and distress, VAS measurements of arousal/anxiety, Tinnitus Handicap Inventory, Quick Inventory of Depressive Symptomatology, and plasma concentrations of trial drugs. RESULTS: No statistically significant treatment benefit effect was detected for tinnitus (intensity, pitch, and distress) VAS scores, arousal-anxiety VAS scores, Tinnitus Handicap Inventory, or tinnitus aggravation scores assessed on Days 1 and 14. However, a statistically significant worsening of tinnitus intensity and distress scores was observed after vestipitant compared with placebo for the mean data collected over the treatment period. No relevant differences in vestipitant plasma concentrations were observed between the subjects given the combination with paroxetine and those receiving vestipitant alone. No specific relationships were observed between tinnitus intensity and vestipitant plasma concentrations. CONCLUSION:
|
Authors | Claire Roberts, Amir Inamdar, Annelize Koch, Pauline Kitchiner, Odile Dewit, Emilio Merlo-Pich, Paolo Fina, Don J McFerran, David M Baguley |
Journal | Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
(Otol Neurotol)
Vol. 32
Issue 5
Pg. 721-7
(Jul 2011)
ISSN: 1537-4505 [Electronic] United States |
PMID | 21646935
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Fluorobenzenes
- Neurokinin-1 Receptor Antagonists
- Piperidines
- Serotonin Uptake Inhibitors
- Paroxetine
- vestipitant
|
Topics |
- Cross-Over Studies
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Fluorobenzenes
- Humans
- Male
- Middle Aged
- Neurokinin-1 Receptor Antagonists
- Paroxetine
(therapeutic use)
- Piperidines
(therapeutic use)
- Selective Serotonin Reuptake Inhibitors
(therapeutic use)
- Tinnitus
(drug therapy)
- Treatment Outcome
|